Barclays
BOLT icon

Barclays’s Bolt Biotherapeutics BOLT Stock Holding History

Barclays’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24 Hold
6
– – ﹤0.01% 4978
2025
Q4 		$33 Hold
6
– – ﹤0.01% 5139
2025
Q3 		$32 Hold
6
– – ﹤0.01% 5334
2025
Q2 		$35 Sell
6
-1
-14% -$7 ﹤0.01% 5131
2025
Q1 		$56 Hold
7
– – ﹤0.01% 5144
2024
Q4 		$74 Hold
7
– – ﹤0.01% 5188
2024
Q3 		$90 Hold
7
– – ﹤0.01% 5186
2024
Q2 		$104 Hold
7
– – ﹤0.01% 4755
2024
Q1 		$195 Hold
7
– – ﹤0.01% 4985
2023
Q4 		$156 Hold
7
– – ﹤0.01% 5159
2023
Q3 		$145 Hold
7
– – ﹤0.01% 4537
2023
Q2 		$178 Hold
7
– – ﹤0.01% 4420
2023
Q1 		$204 Sell
7
-77
-92% -$2.25K ﹤0.01% 4976
2022
Q4 		$2.18K Buy
84
+77
+1,100% +$2.11K ﹤0.01% 5080
2022
Q3 		$0 Sell
7
-6
-46% -$248 ﹤0.01% 4802
2022
Q2 		$0 Sell
13
-465
-97% -$18.1K ﹤0.01% 5028
2022
Q1 		$26K Buy
+478
New +$32.2K ﹤0.01% 4348

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's BOLT Position: Q1 2026 in Review

Barclays held its Bolt Biotherapeutics (BOLT) position steady in Q1 2026 at 6 shares worth $24. The position accounts for ﹤0.01% of the portfolio, ranked #4978.

Barclays first reported a position in BOLT in Q1 2022 and has held it in 17 quarters since. The position peaked at $26K in Q1 2022. 24 funds tracked by Wall St. Rank hold BOLT as of Q1 2026.

  • Barclays held 6 shares of Bolt Biotherapeutics worth $24 as of Q1 2026.
  • Barclays left its Bolt Biotherapeutics share count unchanged in Q1 2026.
  • Bolt Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4978 holding.
  • Barclays first reported a position in Bolt Biotherapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Bolt Biotherapeutics position peaked at $26K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.